Sector News

GSK sells meningitis vaccines to Pfizer

June 22, 2015
Life sciences
GlaxoSmithKline will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer to satisfy regulatory conditions for its asset-swap deal with Novartis.
 
The European Commission and other antitrust regulators were concerned because GSK acquired two rival meningitis vaccines – Menveo and Bexsero – from Novartis as part of the deal, which could have given the company too much power in the market.
 
Nimenrix and Mencevax are older vaccines that had combined sales of £34 million last year. The total value of the transaction with Pfizer is £82 million.
 
“Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need – the prevention of meningococcal disease across all ages,” says Susan Silbermann, president of Pfizer Vaccines.
 
“Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis – an uncommon but serious and sometimes fatal disease.”
 
Last year Pfizer purchased another meningitis vaccine, Baxter’s NeisVac-C, and had its own serogroup B meningococcal disease drug Trumenba approved.
 
The sale is expected to be completed by the end of the year.
 
By George Underwood
 
Source: Pharma Times

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend